Insider trades
Matthew Gline, CEO of Roivant Sciences ROIV, has filed 1 purchase and 5 sales on the open market. Over the past 12 months that comes to a net sale of $46.2M. The latest trade was on 04/16.
Matthew Gline
CEO
- Company
- Roivant Sciences ROIV
- First filing
- 23/01/26
- Trades
- 73 trades
- Buys / sales
- 1 / 5
- 12-month net buying
- −$46.2M
- Last trade
- 04/16
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
Roivant SciencesROIV | Open-market sale | 04/16 | 04/20 | 289,774 sh | $29.16 | $8,449,809.84 | −1.7% |
ROIV | Open-market sale | 25/12/15 | 25/12/17 | 1,740,000 sh3 trades | $21.68avg. | $37,723,200 | −8.5% |
Roivant SciencesROIV | Open-market buy | 25/09/18 | 25/09/18 | 3,315 sh | $15.07 | $49,957.05 | +0.0% |
Roivant SciencesROIV | Open-market sale10b5-1 plan | 24/09/23 | 24/09/24 | 1,983,257 sh | $11.79 | $23,382,600.03 | −10.0% |